DOI: 10.1097/01.OTU.0000398552.15053.93

,  

Issn Print: 1742-8009

Publication Date: 2010/03/01


Print

Metastatic HER2-overexpressing breast tumours do best on combo

Charlene Laino

    loading  Checking for direct PDF access through Ovid

Excerpt

In women with metastatic HER2-overexpressing breast cancer progressing with trastuzumab, adding lapatinib and continuing trastuzumab is more efficacious than using lapatinib alone.
    loading  Loading Related Articles